AMARILLO, TX--(MARKET WIRE)--Apr 14, 2008 -- Amarillo Biosciences, Inc. (OTC BB:
AMAR.OB -
News), a
specialty pharmaceutical company focused on low-dose orally
administered
interferon as a treatment for a variety of conditions, today
announced that
Peter Mueller, Ph.D. has been appointed Chief Operating
Officer and
Director of Research. Dr. Mueller will be responsible for
research and
development, business development, licensing, global commercial
development, production and administration at the company.
He will be
actively involved in the development of strategic alliances
and business
opportunities with other companies and organizations.
Dr. Mueller has more than 20 years of global experience
in the
pharmaceutical industry. Most recently, he has headed Epicenter
Consulting
Inc., a New Jersey-based health care consulting firm that
he founded in
2001. Previously, Dr. Mueller was Vice President, Global
Marketing &
Medical Information and Technology for Aventis Pharmaceuticals.
Prior to
that position, he served as Vice President, Global Marketing
Business &
Marketing Services for Hoechst Marion Roussel. He was also
Director,
Global Commercial Development, Cardiovascular and Metabolism
for Marion
Merrell Dow. Dr. Mueller is a pharmacist with a Ph.D. degree
in
pharmaceuticals from the University of Mainz, Germany.
"Peter is a dynamic and results-driven executive with extensive
global
experience in the pharmaceutical industry," observed Dr.
Joseph Cummins,
President and Chief Executive Officer of Amarillo Biosciences.
"His strong
organizational skills coupled with his dedication to the
achievement of
strategic and tactical objectives, will greatly aid our
company's efforts
to achieve FDA approval for the utilization of our low-dose
interferon in
the treatment of multiple medical conditions."
Dr. Cummins added, "Dr. Mueller's proven track record for
achieving
organizational as well as market-based objectives will be
invaluable to
Amarillo Biosciences. As a consultant, Dr. Mueller completed
major
projects for large pharmaceutical and biotech companies
in the United
States and Europe, and we are highly confident that his
management skills
and network of business associates will accelerate the company's
development of its low-dose interferon technology platform.
I am
particularly delighted that Dr. Mueller's energy and contributions
will
allow me more time to fully study new clinical applications
for oral
interferon and file new patent applications."
"Prior to joining Amarillo Biosciences, I conducted a great
deal of
research and due diligence on the company's technology and
prospects to
target both large and orphan market opportunities, and I
am confident that
the company can rapidly develop into a significant specialty
pharmaceutical
company," said Dr. Mueller.
Dr. Mueller further commented, "Amarillo Biosciences is
on the cusp of
proving the efficacy and benefits of its low-dose oral interferon
technology. The key to its global success will involve the
development of
oral Interferon for the treatment of chronic cough in chronic
obstructive
pulmonary disease (COPD) -- which is estimated to affect
more than 600
million people worldwide -- and for the treatment of influenza
and
hepatitis C, which also have large global market potential."
About Amarillo Biosciences, Inc.
Amarillo Biosciences, Inc. is a U.S. biotechnology firm
operating in global
partnership with the Hayashibara Group, which owns 10.5%
of Amarillo
Biosciences shares and has provided over $18 million in
loans, grants and
equity investments to the company. Amarillo Biosciences'
primary focus
involves extensive and ongoing R&D into the utilization
of low-dose, orally
administered interferon as a treatment for a variety of
conditions,
including chronic cough (COPD), influenza, and opportunistic
infections in
patients who are HIV positive. In its 23-year history, the
Company has
invested nearly $39 million to establish oral interferon
as a therapeutic
agent. The majority of those funds were invested in clinical
trials in an
effort to achieve FDA approval for low-dose oral interferon.
Additional
information is available on the web site at http://www.amarbio.com/.
Except for the historical information contained herein,
the matters
discussed in this news release are forward-looking statements
that involve
risks and uncertainties, including uncertainties related
to product
development, uncertainties related to the need for regulatory
and other
government approvals, dependence on proprietary technology,
uncertainty of
market acceptance of oral interferon or the Company's other
product
candidates and other risks detailed from time to time in
the Company's
filings with the Securities and Exchange Commission. In
particular, see
"Item 1. Description of Business" of the Company's Form
10-KSB for the year
ended December 31, 2007.